EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Muscle satellite cell editing by LNP-CRISPR-Cas9 to resist muscle injury

Taisuke Mochida, Naoko Fujimoto, Makoto Asahina, Shinya Asano, Shinsuke Araki, Naoto Inukai, Akitsu Hotta

Cell Reports · 2026-01 · 45 (1) · 116695

DOI: 10.1016/j.celrep.2025.116695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-01. Verfasst von Taisuke Mochida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Target Validation Sciences, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda-CiRA Joint Program (T-CiRA), Fujisawa, Kanagawa,…. Hauptthemen laut MEDLINE: Satellite Cells, Skeletal Muscle, CRISPR-Cas Systems, Gene Editing, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Satellite Cells, Skeletal MuscleCRISPR-Cas SystemsGene EditingMuscular Dystrophy, DuchenneMuscle, SkeletalNanoparticlesAnimalsMiceMice, Inbred C57BLRNA, Guide, CRISPR-Cas SystemsDisease Models, AnimalMice, Inbred mdxMaleExonsLiposomes

Stichwörter der Autor:innen

AAV vectorCP: stem cell researchCRISPR-SpCas9LNPdeliverygenome editingmuscle stem cellmuscular dystrophysatellite cell

Substanzen

Lipid NanoparticlesRNA, Guide, CRISPR-Cas SystemsLiposomes

Autor:innen und Institutionen

  • Target Validation Sciences, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda-CiRA Joint Program (T-CiRA), Fujisawa, Kanagawa, Japan.
  • Takeda-CiRA Joint Program (T-CiRA), Fujisawa, Kanagawa, Japan; Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan.
  • Takeda-CiRA Joint Program (T-CiRA), Fujisawa, Kanagawa, Japan; Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. Electronic address: akitsu.hotta@ci…

Förderung

  • Takeda Pharmaceutical Company Limited
  • Japan Agency for Medical Research and Development

Zitieren

APA

Mochida, T., Fujimoto, N., Asahina, M., Asano, S., Araki, S., Inukai, N., & Hotta, A. (2026). Muscle satellite cell editing by LNP-CRISPR-Cas9 to resist muscle injury. Cell Reports, 45(1), 116695. https://doi.org/10.1016/j.celrep.2025.116695

Vancouver

Mochida T, Fujimoto N, Asahina M, Asano S, Araki S, Inukai N, et al. Muscle satellite cell editing by LNP-CRISPR-Cas9 to resist muscle injury. Cell Reports. 2026;45(1):116695. doi:10.1016/j.celrep.2025.116695

BibTeX
@article{Mochida2026,
  author = {Mochida, Taisuke and Fujimoto, Naoko and Asahina, Makoto and Asano, Shinya and Araki, Shinsuke and Inukai, Naoto and Hotta, Akitsu},
  title = {Muscle satellite cell editing by LNP-CRISPR-Cas9 to resist muscle injury},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {1},
  pages = {116695},
  doi = {10.1016/j.celrep.2025.116695}
}
Kostenlos starten →